Quintrio
Home

IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Immucell Corp

ICCC

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Last trade $11.43
Day change +$0.005 (+0.04%)
Day range $10.51 – $11.77
Volume 14,957
Market cap $104M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$103.82M
Price / earnings
55.24×
Price / book
3.17×
Price / sales
3.13×
EV / sales
3.13×
EV / EBITDA
14.9×

Profitability

Earnings per share
$0.21
Return on assets
3.92%
Return on equity
5.74%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.24×
Current ratio
4.61×
Quick ratio
2.5×
Cash ratio
1.69×

Cash flow

Price / cash flow
13.26×
Price / free cash flow
19.22×
Free cash flow
$5.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ICCC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$8.04M$7.19M$10.36M$7.63M$5.51M$6.44M$8.07M$7.75M
Cost of revenue$4.48M$4.75M$5.7M$4.72M$3.14M$3.63M$4.71M$4.92M
Gross profit$3.56M$2.44M$4.66M$2.91M$2.36M$2.82M$3.35M$2.83M
Selling, general and administrative$2.42M$2.38M$2.37M$2.21M$1.65M$1.42M$1.48M$1.39M
Research and development$176.77K$119.65K$317.69K$758.86K$694.31K$831.86K$756.85K$819.39K
Total operating expenses$2.6M$502.29K$2.69M$2.97M$2.34M$2.25M$2.24M$2.21M
Operating income$957.77K$1.93M$1.97M-$57.96K$20.08K$569.56K$1.12M$621.4K
Interest expense-$92.53K-$95.67K$0$0-$134.52K-$124.8K$0$0
Income before taxes$935.28K$1.88M$1.95M-$2.85M-$135.29K$503.78K$1.45M$520.59K
Income taxes-$17.24K$45.95K$12.52K$3.31K$4.46K$1.9K$1.9K$6.04K
Net income$952.51K$1.83M$1.94M-$2.85M-$139.75K$501.88K$1.45M$514.56K
Net income attributable to common shareholders$952.51K$1.83M$1.94M-$2.85M-$139.75K$501.88K$1.45M$514.56K
EBITDA$1.42M$2.41M$2.5M$648.36K$699.16K$1.24M$1.79M$1.3M
Basic earnings per share$0.10$0.20$0.21-$0.31-$0.02$0.06$0.16$0.06
Diluted earnings per share$0.10$0.20$0.21-$0.31-$0.02$0.06$0.16$0.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?

Zoetis (ZTS) and ImmuCell (ICCC) operate in animal health but with different profiles. Zoetis offers diversification across companion animals, livestock, and diagnostics but faces near-term headwinds from declining companion animal demand and reduced 2026 guidance. ImmuCell shows stronger recent growth with 20.9% sales increases and expanding market share in calf scours prevention, but carries higher execution risks due to narrow product focus and margin pressures during manufacturing expansion.

Zacks Investment Research

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2

ImmuCell Corporation (ICCC) reported Q2 2026 product sales of $7.19 million, up 11.5% year-over-year, with earnings of 20 cents per share versus 6 cents prior year. However, gross margins contracted significantly to 33.9% from 43.7% due to lower production volumes, material quality issues, and cost reclassifications. The stock declined 8.8% post-earnings. Management highlighted strong domestic sales growth of 27.7% and increased market share for First Defense, but noted international headwinds and manufacturing challenges. The company is investing $8 million in facility expansion expected to triple capacity by end of 2027.

The Motley Fool

ImmuCell Q2 Profit Jumps as Margins Rise

ImmuCell reported Q2 2025 results with improved gross margins and completed First Defense production capacity expansion, but faces ongoing FDA approval delays for Retain product, creating uncertainty in near-term growth trajectory.

GlobeNewswire Inc.

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain®.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.